Clinical Trials in San Diego

Showing 3421-3440 of 12,589 trials

A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder

NCT01114698

The purpose of this study is to evaluate the effectiveness and safety of JNJ26489112 compared with an active control (Venlafaxine XR) and placebo in patients with Treatment-Resistant Major Depressive Disorder.

Depression

Janssen Research & Development, LLC12 participantsStarted Mar 2011

Arcadia, California, United States • Escondido, California, United States • San Diego, California, United States +11 more locations

COMPLETEDPhase 2< 1 mile

A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

NCT03227224

The purpose of this study is to assess the dose-response relationship of 2 doses of JNJ-42847922 before interim analysis, and potentially 3 doses based on interim analysis results, compared to placebo as adjunctive therapy to an antidepressant drug in improving depressive symptoms in participants with Major Depressive Disorder (MDD) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI); and to assess the safety and tolerability of JNJ-42847922 compared to placebo as adjunctive therapy to an antidepressant in participants with MDD.

Depressive Disorder, Major

Janssen Research & Development, LLC287 participantsStarted Aug 2017

Anaheim, California, United States • Chino, California, United States • Lemon Grove, California, United States +98 more locations

A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder

A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

Find Trials by Condition in San Diego

A Study of Paliperidone Palmitate 6-Month Formulation

An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant

ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide

Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

Study of AGEN1571 in Participants With Advanced Solid Tumors

Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)

Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor

Pulmonary Hemodynamics During Exercise - Research Network

A Study of Seltorexant in Participants With Probable Alzheimer's Disease

IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

A Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS)

A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)